JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Fulgent Genetics Inc

Suletud

SektorTervishoid

23.6 0.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23

Max

23.74

Põhinäitajad

By Trading Economics

Sissetulek

-7.4M

-19M

Müük

8.3M

82M

Kasumimarginaal

-23.539

Töötajad

1,313

EBITDA

-3.5M

-15M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.79% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

181M

730M

Eelmine avamishind

22.96

Eelmine sulgemishind

23.6

Uudiste sentiment

By Acuity

50%

50%

163 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Fulgent Genetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

23. okt 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. okt 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. okt 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. okt 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -2-

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. okt 2025, 22:17 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. okt 2025, 21:41 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. okt 2025, 21:05 UTC

Tulu

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. okt 2025, 20:35 UTC

Tulu

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. okt 2025, 20:28 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. okt 2025, 20:15 UTC

Market Talk
Tulu

Global Commodities Roundup: Market Talk

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Adj EPS $1.71

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Sales $5.52B

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q EPS $1.67

23. okt 2025, 20:09 UTC

Tulu

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. okt 2025, 20:07 UTC

Tulu

Blackstone Looks to IPOs for Investment Exits -- Update

23. okt 2025, 20:05 UTC

Tulu

Intel 3Q Gross Margin 38.2% >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. okt 2025, 20:04 UTC

Tulu

Intel: 4Q Guidance Excludes Altera >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Sees 4Q Adj EPS 8c >INTC

Võrdlus sarnastega

Hinnamuutus

Fulgent Genetics Inc Prognoos

Hinnasiht

By TipRanks

7.79% tõus

12 kuu keskmine prognoos

Keskmine 25.33 USD  7.79%

Kõrge 30 USD

Madal 21 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fulgent Genetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

17.32 / 19.04Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

163 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat